Executive Chairman – C. Boyd Clarke
Mr. Clarke’s original training in the pharmaceutical and vaccine industry was received at Merck and Company, where he held positions, including Vice President of the Merck Vaccine Division and the founding President of Pasteur-Merieux MSD, a European joint venture that commercialized vaccines in the European Union. Since leaving Merck in 1996, his career has focused on leading and advising smaller developmental biotechnology and vaccine companies. Mr. Clarke was previously President and Chief Executive Officer of three biotechnology companies: Neose Technologies, a protein therapeutics company; Aviron, a vaccine company; and U.S. Bioscience, an oncology company. MedImmune acquired both Aviron (in 2001) and U.S. Bioscience (in 1999) for a combined value of $2 billion. Mr. Clarke has served as Chairman of the Board of QLT (an ocular company) and Mersana Therapeutics (an oncology company), and as Executive Chairman of LigoCyte Pharmaceuticals (a vaccine company), in which he oversaw the sale of the company to Takeda Pharamceuticals in 2012. He also served as a Board member or advisor to several other smaller companies. In these capacities, he has developed significant expertise in the challenges of small company leadership, strategic management, business development, and mergers and acquisitions.
Phillip M. Halpern
Philip M. Halpern is the managing partner of the law firm of Collier, Halpern, Newberg, Nolletti & Bock, LLP, with offices in New York City, White Plains and Stamford, Connecticut. Mr. Halpern is a magna cum laude graduate of Fordham University, where he majored in economics, and is a graduate of Pace University School of Law where he obtained his juris doctor.
Mr. Halpern actively practices law in the states of New York and Connecticut. He has been certified by the National Board of Trial Advocacy as a civil trial advocate and civil pre-trial advocate. Mr. Halpern has authored a two-volume book for Thompson Publishing Company on civil procedure (with annual updates). He has also authored several articles for the New York State Bar Association and the American Bar Association and has lectured for the Office of Court Administration, New York State Bar Association, The Elisabeth Haub School of Law at Pace University and a number of Bar Associations on a variety of litigation topics. His articles include “Age Discrimination in Employment: Releases Protect Employers Too!” which was published in The Labor Lawyer, American Bar Association, in 1993, “Fair Value Proceedings: Fixing Fair Value In New York,” which was published in the NY Litigator, New York State Bar Association, Commercial and Federal Litigation Section, in 1996, “Court of Appeals Sharply Diminishes the Substantive Due Process Rights of Property Owners,” which was published in The NY Litigator, New York State Bar Association, Commercial and Federal Litigation Section, in 2006, “Unlocking a Valuable Tool: Summary Judgment Hearings on Issues of Fact,” published in the Westchester Bar Journal, Westchester County Bar Association in 2006, “The Contours of Common-Law Dissolution in New York,” published in the NY Litigator , New York State Bar Association, Commercial and Federal Litigation Section in 2007 and “Mixing Law and Equity Causes of Action Does Not Preclude a Jury Trial,” published in the Pace Law Review, Spring 2015.
Additionally, Mr. Halpern is an Adjunct Professor at The Elisabeth Haub School of Law at Pace University and teaches a class entitled, “The Anatomy of a Trial: The Burden of Proof,” which deals exclusively with trial skills and is also writing a textbook for the class. He is a mediator in Federal Court, Southern District of New York and in New York State Supreme Court, Ninth Judicial District, Commercial Division, Westchester County.
Mr. Halpern is a Fellow of the American Bar Foundation and member of the Office of Court Administration’s Advisory Committee on Civil Practice. Mr. Halpern has been a member of the Advisory Council for the Board of Judges for the Southern District of New York. Mr. Halpern is a member of the Association of the Bar of the City of New York, the Committee on Federal Judiciary for the New York State Bar Association, the American Bar Association, the New York County Lawyers Association, New York State Trial Lawyers Association, the Association of Trial Lawyers of America, and the Federal Bar Council. Mr. Halpern began his legal career in 1980 as a law clerk to a federal judge in the Southern District of New York.
Mr. Halpern joined the Westchester Country Club in June 1984, was its President from 2007 to 2010 and formerly held the office of Chairman from 2010-2013. Additionally, Mr. Halpern is a member of the Advisory Council for the Metropolitan Section of the Professional Golfer’s Association, the Hudson Valley KeyBank Advisory Board, the Board of Directors of the Montel Williams MS Foundation, and the Board of Visitors of Pace University School of Law. He is the 2006 recipient of the Alumni Leadership Award from Pace Law School, the 2007 Pace Setter Award from the Westchester Business Journal and in 2008 was honored by the American Diabetes Association as Father of the Year. In 2017, he was honored by the Legal Services of the Hudson Valley for his steadfast devotion to its mission and his significant pro-bono activities to help those in need of litigation services.
Paul V. Radspinner
Mr. Radspinner is co-founder, President and Chief Executive Officer of FluGen Inc. which he co-founded with Drs. Yoshihiro Kawaoka and Gabriele Neumann in June of 2007. With Mr. Radspinner as President & CEO FluGen has raised over $25 million in capital and completed its first-in-man study of M2SR “RedeeFlu” earlier this year. After completing his MBA at Northwestern University’s Kellogg Graduate School of Management he spent over 15 years in management roles overseeing international pharmaceutical operations, marketing and business development with Eli Lilly and Company. After his time at Lilly he managed the pharmaceuticals portfolio including Vitamin D analogs at the Wisconsin Alumni Research Foundation (WARF) for the University of Wisconsin-Madison. Mr. Radspinner entered the Madison biotech scene when he took on the role of Vice President of Business Development for Deltanoid Pharmaceuticals, Inc. and then started FluGen. In 2008 Mr. Radspinner was elected to the Board of Directors for BioForward, the Wisconsin state biotechnology organization where he served as President. Mr. Radspinner is a member of the Boards of Directors for Plumb Pharmaceuticals, Pan Genome Sciences and Co-D Therapeutics.
Dan Stinchcomb, PhD
Dr. Stinchcomb is Chief Scientific Officer at the Infectious Disease Research Institution, where he is focusing on developing lower cost vaccines, diagnostics and therapeutics for infectious disease threats worldwide. Prior to joining IDRI, Dr. Stinchcomb was Founder and Principal of Global H, LLC a scientific consulting group that advised vaccine and infectious disease groups worldwide. Previously, Dr. Stinchcomb was Chief Executive Officer of Inviragen, which he co-founded in 2005. Under his leadership, Inviragen grew from a two employee start-up to an international clinical stage company focusing on infectious disease vaccines. Inviragen advanced vaccines for dengue fever and hand, foot and mouth disease from research to proof-of-concept human clinical trials and developed several vaccine candidates through advanced preclinical testing. Dr. Stinchcomb completed numerous partnerships and collaborations, executed a merger with an Asian vaccine company, and raised over $30 million in grants and contracts and over $30 million in equity financing. Inviragen was successfully acquired by Takeda in May of 2013. Dr. Stinchcomb has twenty-nine years of biotechnology experience including research, product development, and approval of vaccines, therapeutics, and diagnostics. His background includes positions as Executive Vice President of Research and Development at Heska Corporation, senior scientific management positions at Ribozyme Pharmaceuticals (acquired by Merck) and at Synergen (acquired by Amgen). He started his career as an Assistant and Associate Professor in Cellular and Developmental Biology at Harvard University and post-doctoral fellow at University of Colorado. Dr. Stinchcomb holds a Ph.D. in biochemistry from Stanford University and a B.A. in biology from Harvard College.
Mr. Walsh is a retired Partner and former managing partner in the law firm Foley & Lardner LLP. He received his bachelor’s degree from the University of Wisconsin-Madison (1965) and his J.D. degree from Harvard Law School (1970). In 1997, he received the Distinguished Business Alumnus Award from the University’s School of Business and in 2012 he received the Distinguished Alumnus Award from the University of Wisconsin-Madison. Mr. Walsh was Chair of the UW Hospital and Clinics Authority Board (2008 – 2015). He served on the University of Wisconsin System Board of Regents (2003-2015), where he served as President from 2005-2007. Mr. Walsh is currently a Board member of Thompson Investment Management, LLC, Chairman of the Board at National Guardian Life Insurance Company, and is on the investment committee for the Kegonsa Seed Fund I, L.P. Mr. Walsh was a Lieutenant in the United States Navy and served in Vietnam (1966-1967).
Dr. Weiss has been a member of the FluGen board since 2015. He joined Venture Investors in 2006 as a Managing Director, and focuses on making Healthcare investments.
Dr. Weiss has over 20 years of operating experience in the biotech and pharmaceutical industries. He previously was President of the Gala Biotech business unit of Cardinal Health (now Catalent Pharma solutions). Before joining Gala, he served as the VP of Business Development for 3-Dimensional Pharmaceuticals, a biotechnology company that completed its IPO during his tenure, and was subsequently acquired by Johnson & Johnson. Earlier in his career, Dr. Weiss worked as Director of Licensing for Wyeth-Ayerst Pharmaceuticals, (now Pfizer). He also served as Director of Business Development and Research for Scientific Protein Labs, a division of American Home Products, and Director of Operations for Columbia Research Labs, now Juniper Pharmaceuticals (NASDAQ: JNP), a publicly held company that focuses on women’s health.
In addition to FluGen, Dr. Weiss is currently a member of the Board of Directors for Aerpio Pharmaceuticals (OTCQB: ARPO) and Madison Vaccines Incorporated, and is an observer at Tissue Regeneration Systems. Dr. Weiss also serves on the Board of Directors for TamirBio (formerly Alfacell Corporation (NASDAQ: ACEL), and on the Board of Visitors for the Waisman Center and Waisman Biomanufacturing at the University of Wisconsin-Madison. Dr. Weiss was previously on the boards of Akebia Therapeutics (NASDAQ: AKBA) and Neurovance (sold to Otsuka Pharmaceuticals)